Chemotherapy regimen for recurrent uterine leiomyosarcoma

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Pharmacology

Background:

• Uterine leiomyosarcoma is a rare gynecologic malignancy with no established optimal chemotherapy.
• Current treatment guidelines lack high-level clinical evidence, leading to varied therapeutic approaches.

Observation:

• A patient with uterine leiomyosarcoma experienced disease recurrence after receiving doxorubicin, gemcitabine, docetaxel, and anlotinib.
• The patient was subsequently treated with a combination regimen of liposomal doxorubicin and dacarbazine.

Findings:

• The liposomal doxorubicin and dacarbazine regimen was administered intravenously every 21 days.
• The treatment was well-tolerated, with no significant adverse effects reported during the monitoring period.

Implications:

• This case highlights the potential efficacy of liposomal doxorubicin combined with dacarbazine for recurrent uterine leiomyosarcoma.
• Individualized treatment planning, considering patient condition and drug-specific profiles, is crucial for optimizing therapeutic outcomes in rare gynecologic cancers.